title: Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes.
abstract: BACKGROUND
  Dapagliflozin (DAPA) (Farxiga or Forxiga) is a sodium glucose cotransporter 2 (SGLT2) inhibitor approved for type 2 diabetes mellitus(T2DM) treatment.
  
  
  METHODS
  The review focuses on the pharmacokinetics (PK), pharmacodynamics(PD) and clinical studies published on DAPA. The authors searched PubMed database for English language studies describing DAPA characteristics and use in T2DM subjects published through June 2014.
  
  
  CONCLUSIONS
  DAPA exhibits favorable PK and PD properties and is effective in reducing glycemic levels. In addition, DAPA shows beneficial/neutral effects on other risk factors contributing to T2DM metabolic control. Increased risk of genital and urinary infections and episodes of volume depletion represent the major concerns for its use. FDA requires additional data to assess imbalances in bladder cancer and drug cardiovascular safety. The mechanism of action and the very low risk of drug-drug interaction make it an ideal drug for rapidly reducing glucotoxicity and restoring clinical response to other antidiabetic drugs.
authors.affiliation: University of Rome "Sapienza", Department of Internal Medicine and Clinical Specialities , V.le del Policlinico, 155, 00161, Rome , Italy +39 0 6 49978301 ; +39 0 6 4463783 ; sebastiano.filetti@uniroma1.it.
authors.forename: Marianna
authors.initials: M
authors.lastname: Maranghi
authors.forename: Anna
authors.initials: A
authors.lastname: Carnovale
authors.forename: Cosimo
authors.initials: C
authors.lastname: Durante
authors.forename: Giovanna
authors.initials: G
authors.lastname: Tarquini
authors.forename: Giusy
authors.initials: G
authors.lastname: Tiseo
authors.forename: Sebastiano
authors.initials: S
authors.lastname: Filetti
mesh_terms: D000818:Animals; D001559:Benzhydryl Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D005960:Glucosides / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D051247:Sodium-Glucose Transport Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; D051247:Sodium-Glucose Transport Proteins; C529054:dapagliflozin
keywords: SGLT2 inhibitors; dapagliflozin; kidney; type 2 diabetes